neobookRx
GuidelinesOther guideline

References

Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: Data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12(2):R42. https://doi.org/10.1186/ar2951 Bombardier C, Barbieri M, Parthan A, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: A systematic review. Ann Rheum Dis 2

  1. Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: Data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12(2):R42. https://doi.org/10.1186/ar2951
  2. Bombardier C, Barbieri M, Parthan A, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: A systematic review. Ann Rheum Dis 2012;71(6):836-844. https:// doi.org/10.1136/annrheumdis-2011-200343
  3. Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: A pooled analysis of clinical trial results. Ann Rheum Dis 2008;67(2):238-243. https://doi.org/10.1136/ard.2007.071415
  4. Conigliaro P, D’Antonio A, D’Erme L, et al. Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy. PLoS ONE 2023;18(2):e0281213. https://doi.org/10.1371/journal.pone.0281213
  5. Yerima A, Akintayo R, Adebajo A. Implications of a diagnosis of rheumatoid arthritis in resourcepoor countries. Best Pract Res Clin Rheumatol 2022;36(1):101725. https://doi.org/10.1016/j. berh.2021.101725
  6. Hulsmans HM, Jacobs JW, van der Heijde DM, van Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43(9):1927-1940. https://doi.org/10.1002/1529-0131(200009)43:93.0.CO;2-B
  7. O’Dell JR. How is it best to treat early rheumatoid arthritis patients? Best Pract Res Clin Rheumatol 2001;15(1):125-137. https://doi.org/10.1053/berh.2000.0130
  8. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43(7):906-914. https://doi.org/10.1093/rheumatology/keh199
  9. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21(4):663- 675. https://doi.org/10.1016/j.berh.2007.02.004
  10. Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: A systematic literature review. Ann Rheum Dis 2014;73(1):114-123. https:// doi.org/10.1136/annrheumdis-2013-203284
  11. Van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 2017;76(3):491-496. https://doi. org/10.1136/annrheumdis-2016-209846
  12. Burgers LE, Siljehult F, Ten Brinck RM, et al. Validation of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Rheumatology (Oxford) 2017;56(12):2123-2128. https://doi.org/10.1093/rheumatology/kex324
  13. Smolen JS, Aletaha D. The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 2010;28(3 Suppl 59):S18-S27.
  14. Van der Heijde DM, van’t Hof MA, van Riel PL, van de Putte L. Disease activity score. Ann Rheum Dis 1992;51(1):140.
  15. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S100-S108.
  16. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res Ther 2005;7(4):R796-R806. https://doi.org/10.1186/ar1740
  17. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23(2):137-145. https://doi.org/10.1002/art.1780230202
  18. Wakefield RJ, Green MJ, Marzo-Ortega H, et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 2004;63(4):382-385. https://doi. org/10.1136/ard.2003.007062
  19. Kgoebane K, Ally M, Duim-Beytell MC, Suleman FE. The role of imaging in rheumatoid arthritis. SA J Radiol 2018;22(1):1316. https://doi.org/10.4102/sajr.v22i1.1316
  20. Agrawal S, Bhagat SS, Dasgupta B. Improvement in diagnosis and management of musculoskeletal conditions with one-stop clinic-based ultrasonography. Mod Rheumatol 2009;19(1):53-56. https://doi. org/10.1007/s10165-008-0122-4
  21. Dale J, Stirling A, Zhang R, et al. Targeting ultrasound remission in early rheumatoid arthritis: The results of the TaSER study, a randomised clinical trial. Ann Rheum Dis 2016;75(6):1043-1050. https:// doi.org/10.1136/annrheumdis-2015-208941
  22. Haavardsholm EA, Aga AB, Olsen IC, et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 2016;354:i4205. https://doi.org/10.1136/bmj.i4205
  23. Smolen JS, Landewé RB, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82(1):3-18. https://doi.org/10.1136/ard-2022-223356
  24. Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis 2015;74(6):954-962. https://doi.org/10.1136/ annrheumdis-2014-206807
  25. Marques A, Santos E, Nikiphorou E, Bosworth A, Carmona L. Effectiveness of self-management interventions in inflammatory arthritis: A systematic review informing the 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. RMD Open 2021;7(2):e001647. https://doi.org/10.1136/rmdopen-2021-001647
  26. Kyburz D, Gabay C, Michel BA, Finckh A; physicians of SCQM-RA. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: A population-based cohort study. Rheumatology (Oxford) 2011;50(6):1106-1110. https://doi.org/10.1093/rheumatology/keq424
  27. Feldman DE, Bernatsky S, Houde M, Beauchamp ME, Abrahamowicz M. Early consultation with a rheumatologist for RA: Does it reduce subsequent use of orthopaedic surgery? Rheumatology (Oxford) 2013;52(3):452-459. https://doi.org/10.1093/rheumatology/kes231
  28. Hill J. Rheumatology nurse specialists – do we need them? Rheumatology (Oxford) 2007;46(3):379- 381. https://doi.org/10.1093/rheumatology/kel431
  29. Baka Z, Buzas E, Nagy G. Rheumatoid arthritis and smoking: Putting the pieces together. Arthritis Res Ther 2009;11(4):238. https://doi.org/10.1186/ar2751
  30. Sobue Y, Kojima T, Ito H, et al. Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis. Mod Rheumatol 2022;32(1):96-104. https://doi.org/10.1 080/14397595.2021.1886653
  31. Ajeganova S, Andersson ML, Hafstrom I; BARFOT Study Group. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long-term followup from disease onset. Arthritis Care Res (Hoboken) 2013;65(1):78-87. https://doi.org/10.1002/acr.21710
  32. Kreps DJ, Halperin F, Desai SP, et al. Association of weight loss with improved disease activity in patients with rheumatoid arthritis: A retrospective analysis using electronic medical record data. Int J Clin Rheumatol 2018;13(1):1-10. https://doi.org/10.4172/1758-4272.1000154
  33. Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 2013;52(10):1809-1817. https://doi.org/10.1093/rheumatology/ket224
  34. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73(1):62-68. https://doi.org/10.1136/annrheumdis-2013-204223
  35. Farhat H, Irfan H, Muthiah K, et al. Increased risk of cardiovascular diseases in rheumatoid arthritis: A systematic review. Cureus 2022;14(12):e32308. https://doi.org/10.7759/cureus.32308
  36. Scott IC, Machin A, Mallen CD, Hider SL. The extra-articular impacts of rheumatoid arthritis: Moving towards holistic care. BMC Rheumatol 2018;2:32. https://doi.org/10.1186/s41927-018-0039-2
  37. Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Ann Rheum Dis 2023;82(1):74-80. https://doi.org/10.1136/ ard-2022-223413
  38. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69(4):631-637. https://doi.org/10.1136/ard.2009.123919
  39. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364(9430):263- 269. https://doi.org/10.1016/S0140-6736(04)16676-2
  40. Solomon A, Stanwix AE, Castaneda S, et al. Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. BMC Rheumatol 2020;4:42. https://doi.org/10.1186/s41927-020-00139-2
  41. Hetland ML, Haavardsholm EA, Rudin A, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020;371:m4328. https://doi.org/10.1136/bmj.m4328
  42. Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 2022;81(1):20-33. https://doi.org/10.1136/ annrheumdis-2021-220973
  43. Van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomised, doubleblind, placebo-controlled study. Arthritis Rheum 2001;44(7):1515-1524. https://doi.org/10.1002/1529- 0131(200107)44:73.0.CO;2-7
  44. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2021;73(7):924-939. https://doi. org/10.1002/acr.24596
  45. Yazici Y, Erkan D, Paget SA. Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: Is it time to update the guidelines? J Rheumatol 2002;29(8):1586-1589.
  46. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann Rheum Dis 2009;68(7):1100-1104. https:// doi.org/10.1136/ard.2008.093690
  47. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: The randomised CONCERTO trial. Ann Rheum Dis 2015;74(6):1037- 1044. https://doi.org/10.1136/annrheumdis-2013-204769
  48. Padjen I, Crnogaj MR, Anic B. Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms. Reumatologia 2020;58(6):390-400. https:// doi.org/10.5114/reum.2020.101400
  49. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41(9):1552-1563. https://doi.org/10.1002/1529- 0131(199809)41:93.0.CO;2-W
  50. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388(10055):2023-2038. https:// doi.org/10.1016/S0140-6736(16)30173-8
  51. Ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347(8998):347-352. https://doi.org/10.1016/ s0140-6736(96)90535-8
  52. Van Mulligen E, de Jong PHP, Kuijper TM, et al. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: First-year results of the randomised controlled TARA study. Ann Rheum Dis 2019;78(6):746-753. https://doi. org/10.1136/annrheumdis-2018-214970
  53. Tanaka Y, Hirata S, Saleem B, Emery P. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013;31(4 Suppl 78):S22-S27.
  54. Kim SC, Solomon DH. Towards defining the safer use of opioids in rheumatology. Nat Rev Rheumatol 2020;16(2):71-72. https://doi.org/10.1038/s41584-019-0360-1
  55. Chan FK, Abraham NS, Scheiman JM, Laine L; First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: A clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008;103(11):2908-2918. https://doi.org/10.1111/j.1572-0241.2008.02200.x
  56. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-1644. https://doi.org/10.1001/jama.296.13.jrv60011
  57. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68(7):1086-1093. https://doi.org/10.1136/ard.2008.094474
  58. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7,527 patients. Arthritis Rheum 2003;48(10):2750-2762. https://doi.org/10.1002/art.11439
  59. Roodenrijs NMT, Welsing PMJ, van der Goes MC, et al. Healthcare utilisation and economic burden of difficult-to-treat rheumatoid arthritis: A cost-of-illness study. Rheumatology (Oxford) 2021;60(10):4681-4690. https://doi.org/10.1093/rheumatology/keab078
  60. Bergman M, Zhou L, Patel P, Sawant R, Clewell J, Tundia N. Healthcare costs of not achieving remission in patients with rheumatoid arthritis in the United States: A retrospective cohort study. Adv Ther 2021;38(5):2558-2570. https://doi.org/10.1007/s12325-021-01730-w

Click here to access the pdf.

Tarr, G., Govind, N., Seboka, M., Gardiner, E., & Hodkinson, B. (2024). South African Rheumatism and Arthritis Association 2024 updated guidelines for the management of rheumatoid arthritis. South African Medical Journal, 114(9), e2598. 

Drugs mentioned

ICD-10 codes

NeoHealth® ID 37096 · updated 10/27/2024